Company intelligence / Profile preview

Zhengzhou Taiji Hongnuo Pharmaceutical

Zhengzhou, Henan, China

Ownership: Private
Development stage: Other

Overview

The company is engaged as an active clinical collaborator or partner on the development of TY-302, a CDK4/6 inhibitor at Phase 2 for breast and prostate cancer, and has participated in Phase 1 studies for advanced malignancies and hematologic neoplasms. Its development operations support innovative small molecule oncology assets, led and originated by TYK Medicines.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

TYK Medicines

Beyond the preview

Go deeper on Zhengzhou Taiji Hongnuo Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengzhou Taiji Hongnuo Pharmaceutical.

Explore the full profile